A natomical barriers that protect the developing human fetus also limit our ability to safely and ethically access and observe the human fetus in an ongoing live pregnancy. Historically, knowledge about fetal development, normal or anomalous, was derived from investigation of either aborted fetuses, the placenta after delivery or cultured cells from amniotic fluid obtained for diagnostic purposes. These tissues have been effectively used to obtain powerful information about human development, but are nonetheless imperfect proxies for the living fetus. Terminated fetuses have been subject to trauma, and prolonged cell-culture often results in genetic changes (Sambuy et al. 2005; Li et al. 2007 ). Other fetal material used for diagnostic purposes includes cell-free DNA in the maternal blood, which has been applied clinically for fetal Rhesus D detection and gender determination since 2001 (Lewis et al. 2012; Clausen 2014; Hyland et al. 2014) . More recently, cell-free fetal (cff ) DNA in maternal plasma has been used to screen for fetal aneuploidies (Song et al. 2013; Bianchi et al. 2014) . Maternal blood contains both fetal and maternal cell-free nucleic acids, but the fetal contribution to plasma cellfree DNA is a minority (Canick et al. 2013; Rava et al. 2014) . To examine pure fetal nucleic acids, therefore, fetal sources such as chorionic villi, placenta or amniotic fluid (AF) must be obtained through a diagnostic procedure.
AF refers to both the cellular and noncellular components of amniotic fluid, as well as the liquid itself. It is created from maternal blood plasma in the first trimester, but later comprised primarily of fetal urine, making it a much more concentrated source of fetal material than other maternal biofluids. It is a complex biofluid, containing both membrane-bound fetal cells (amniocytes) and myriad cell-free components, including placenta-derived microparticles, proteins, cffDNA and cffRNA from the fetus (Fig. 1 ) (Larrabee et al. 2005) . Amniocytes are suspended in the AF, and sometimes undergo programmed cell-death, releasing cell-free transcripts. cffRNA may also contain transcripts from fetal tissues not directly in contact with AF (Hui et al. 2012a) . During the first 20 wk of pregnancy, diffusion between the fetus and the AF is bidirectional via fetal skin, which is not yet keratinized (Visscher and Narendran 2014) . This permeable membrane may provide avenues for cffRNA originating in diverse tissues to contribute to the extracellular RNA found in the AF.
Amniotic fluid removed by amniocentesis can be analyzed in the laboratory setting. Centrifugation of the AF separates the amniocytes from the amniotic fluid supernatant (AFS), within which are suspended cff transcripts. The diverse types of cffRNA found in AFS reflect the cellular processes active at the time the cells of origin underwent apoptosis-a time capsule from a distinct moment in fetal development. This information can be used to monitor the development of the fetus while characterizing the effects of naturally occurring perturbations, whether genetic or environmental.
In our laboratory, we have examined the AF transcriptome to measure up-to-the-moment cellular processes occurring in the live human fetus. Isolation and amplification of AFS transcripts, in tandem with a DNAse treatment to preclude genomic DNA contamination, results in a diverse mixture of cffRNA that can be interrogated with high-throughput genomics assays, including expression microarrays. The bioinformatic data resulting from these expression studies can be further examined using in silico functional analyses to investigate the origin of the transcripts and the larger biological 
METHODS
We have capitalized on the abundance of these AFS transcripts to characterize normal fetal development (Hui et al. 2012a (Hui et al. , 2013a while performing discovery-driven research into the developmental underpinnings of several common genetic and nongenetic diseases, each of which will be explored here (Fig. 2, Table 1 ). Each of these studies made use of cffRNA in residual AF specimens collected for routine clinical indications and used similar methodological approaches (Fig. 3) . The RNA was extracted, amplified, labeled and hybridized to either the Affymetrix U133A expression microarray (Larrabee et al. 2005) or the Affymetrix GeneChip Human Genome U133 Plus 2.0 expression microarray (Slonim et al. 2009; Koide et al. 2011; Hui et al. 2012a Hui et al. ,b, 2013a Edlow et al. 2014; Massingham et al. 2014) . Despite the availability of more sophisticated expression microarrays, the U133 Plus 2.0 was chosen because of the need for compatibility with an essential downstream in silico tool, the Connectivity Map (Lamb et al. 2006) . For each study, microarray hybridization signal adjustment, normalization, and summary (Bolstad 2004) were followed by either paired or unpaired t-tests, with a Benjamini -Hochberg (BH) multiple hypothesis correction (Benjamini and Hochberg 1995) to reveal significantly differentially regulated genes.
Each study identified candidate genes of interest through application of specific thresholds for significance based on corrected p-values, consistency among samples, magnitude of fold-change gene expression, and manual literature searches. Identification of misregulated gene expression pathways and tissue-specific expression was undertaken with a variety of powerful and well established in silico functional genomic analysis tools (Box 1).
STUDIES IN THE DEVELOPING FETUS
The majority of amniocenteses are performed in the second trimester of pregnancy, between 15 and 21 weeks' gestational age (GA). Common indications for this diagnostic procedure include advanced maternal age and soft markers for aneuploidies, such as elevated levels of alpha-fetoprotein in the maternal serum or an ultrasonographic observation of an enlarged nuchal fold or an echogenic focus in the fetus. In many cases, karyotyping confirms that the fetus is in fact euploid, and a healthy pregnancy follows. cffRNA from these samples can serve as a control for comparison against cffRNA from fetuses with diagnosed diseases.
Preliminary Studies: Disease, Gestational Age and Gender
The first in vivo whole-transcriptome microarray study of the living human fetus was a proofof-principle experiment designed to consider Figure 2 . Cell-free fetal RNA in amniotic fluid supernatant provides an opportunity to study fetal gene expression in real-time. questions about the effects of sex, GA, and disease on the transcripts present in AFS (Larrabee et al. 2005) . AF was obtained from four pregnancies in which each woman underwent therapeutic amnioreduction for polyhydramnios caused by twin -twin transfusion syndrome (TTTS) or fetal hydrops. GA ranged from 20 to 32 wk for the three male and one female fetal cases. cffRNA from the pooled AFS of six unaffected euploid male fetuses (average GA ¼ 17 wk) was used as a control. Between 15% and 29% of probe sets showed differential ex- pression when compared between the TTTS cases and the pooled male control. Genes of particular relevance to the pathophysiology of hydrops or TTTS were examined, with significantly differential expression of aquaporin 1 (AQP1). These findings served as the basis for a subsequent, more thorough, examination of the effects of TTTS on fetal development (Hui et al. 2013b ). Additionally, gene families known to be involved in fetal lung, skin and gastrointestinal development (surfactant, keratin, and mucin) showed differential expression between the control and cases. This suggested that the population of cffRNA present in AFS is affected by the sex and GA of the fetus. Outside the scope of this review, additional work has since been undertaken, which reveals marked differences between gene expression in the second and third trimesters of euploid fetal life (Hui et al. 2013a ).
BOX 1. RESOURCES FOR IN SILICO FUNCTIONAL ANALYSES
The Online Mendelian Inheritance in Man Database (OMIM) (see http://www.omim.org) is an online catalog of human genes and genetic disorders. This comprehensive database provides references to relevant molecular and clinical research. BioGPS (see https://biogps.org, Wu et al. 2009 ) is a centralized aggregation of protein-coding gene expression data for 78 noncancerous human tissues, including four tissues of fetal origin, and the placenta. Organ specificity was defined by a single organ expression value greater than 30 multiples of the median with the next highest organ expression at no more than one-third the maximum level. A limitation of BioGPS is that it lacks expression profiles for two fetal tissues of relevance to amniotic fluid-kidney and skin.
The Database for Annotation, Visualization and Integrated Discovery (DAVID) (http://david.abcc .ncifcrf.gov, Dennis et al. 2003) synthesizes data from publicly available gene expression atlases into gene enrichment profiles for hundreds of normal and diseased human tissues. Given a list of expressed genes, DAVID can suggest the most likely tissues of origin and identify misregulated pathways.
QIAGEN's Ingenuity Pathway Analysis (IPA) (see http://www.ingenuity.com/products/ipa) is a commercially available platform to identify gene expression pathways enriched within a given data set. IPA will analyze a list of differentially expressed genes to suggest misregulated pathways and cellular functions. IPA has also been used with lists of expressed genes to identify active functions in a given population of fetuses.
Gene Set Enrichment Analysis (GSEA) (see http://www.broadinstitute.org/gsea/index.jsp, Subramanian et al. 2005) can identify sets of genes that are consistently differentially regulated as a group, even when the differential expression of individual genes lacks statistical significance. The Developmental FunctionaL Annotation project at Tufts (DFLAT) (see http://dflat.cs.tufts.edu/data .htm, Wick et al. 2014 ) is gene ontology annotation specific to the developing human fetus. This database can be used with GSEA to identify developmental processes and functions associated with the observed differential gene expression.
The Connectivity Map (CMap) (see https://www.broadinstitute.org/cmap/, Lamb et al. 2006 ) is a database of gene expression signatures resulting from the treatment of human cell lines with known FDA-approved drugs. Associated software uses these signatures to suggest drugs that are expected to reverse the user-provided disease-associated gene expression patterns.
The Library of Integrated Network-Based Cellular Signatures (LINCS) (see http://www .lincsproject.org, Duan et al. 2014) shows the observed and predicted gene expression profile effects of treating 20 cell types with 4000 small molecule drugs. LINCS is an extension of CMap that shares the same goal of identifying drugs with a strong therapeutic potential to correct gene expression misregulation.
Developed by the Reproductive Toxicology Center, Reprotox (see http://www.reprotox.org) is a database summarizing the effects of various chemicals, infections and environmental toxins on reproductive health, pregnancy, and fetal development.
Absent from these data was evidence of several genes known to be expressed specifically in the placenta, including corticotropin-releasing hormone (CRH), chorionic somatomammotropin hormone 1 ( placental lactogen), and the beta subunit of chorionic gonadotropin (bhCG) . This led to the conclusion that the placenta did not contribute to AFS cffRNA. More recent experiments, however, suggest that this conclusion may have been incomplete. Subsequent to this early work, changes in the RNA extraction technique to a superior columnbased protocol, the improved chemistry of the amplification system, and an increased number of samples studied, may all contribute to the fact that more recent evidence shows that AFS does show expression of genes that are specific to the placenta (Hui et al. 2012a) .
Our laboratory recently conducted a study comparing transcriptomes obtained from the AFS cffRNA and the first-passage amniocytes of eight fetuses (see section Applications to Fetal Therapy, below). In this study, we found that 40 unique placenta-specific genes are present in either the amniocytes or AF of at least seven of the eight individuals (Table 2 ). These analyses suggest that either the placenta does in fact contribute cffRNA to the AFS and cells to the population of amniocytes, or that these genes are not in fact specific to the placenta, but rather are expressed from other fetal tissues.
The Second Trimester Euploid Fetus
In 2012, Hui et al. performed a meta-analysis of previously published euploid fetal transcriptomes, considering only those genes expressed by all 12 of the subjects (six male, six female, GA ¼ 16 -21 wk) (Hui et al. 2012a ). This "amniotic fluid core transcriptome" comprised 476 well-annotated genes, including 23 transcripts that were previously known to be expressed in a tissue-specific manner (including those from the liver, lung, and fetal brain). Additionally, functional analysis indicated that the 476 genes reported on six distinct physiologic functions, including musculoskeletal and nervous system development and function. This study detailed the biological richness of amniotic fluid and the contribution of many organ systems to AFS cffRNA, including those not in direct physical contact with amniotic fluid at the time of amniocentesis. An important implication of this work is the suitability of using cffRNA for the 
Genes for which probe set(s) known to have placentaspecific expression are observed as present in more than seven of the eight samples of either amniotic fluid supernatant (AFS), amniocytes (AC) or both. study of developmental disorders affecting a variety of fetal tissues, including those involving the central nervous system.
Genetic Disorders: Down Syndrome
Down syndrome (DS) is estimated to occur in 1:691 live births, making it the most common genetic cause of intellectual disability (Parker et al. 2010 ). The disease is caused by a partial or complete trisomy of chromosome 21 (Lejeune et al. 1959) and results in a variety of physical differences, including short stature, cardiac defects, intellectual disability, and early-onset dementia. In the United States, prenatal screening for DS is offered for all pregnancies, but in the case of a positive diagnosis, there is no fetal treatment available.
In 2009, work from Slonim et al. began to compare the development of second trimester fetuses with DS (caused by a full trisomy 21, T21) to that of healthy euploid fetuses (Slonim et al. 2009 ). Expression microarray studies revealed a set of genes significantly differentially regulated between the seven age-and sexmatched pairs of fetuses. Of the 414 probe sets found to be differentially regulated, only five were located on chromosome 21. Using GSEA, a second set of genes, located on chr21q22, was found to be significantly up-regulated as a group, although the individual genes did not show significant signals of dysregulation. Importantly, the level of up-regulation for all 515 genes represented on the array from chromosome 21 was not simply the 1.5-fold that might be expected because of the presence of a third copy of chromosome 21. Rather, expression differences ranged from fivefold down-regulation to 16-fold up-regulation, suggesting that T21 results in complex intragenomic transcription dysregulation in the fetus. Using DAVID, the list of differentially expressed genes was examined for signatures of disrupted cellular processes. Slonim et al. concluded that the excess of reactive oxygen species in fetal cells disrupts ion transport and signal transduction, leading to pathological symptoms in both neural and cardiac tissues. Oxidative stress had previously been identified in DS (Esposito et al. 2008) , but this was the first study to identify the misregulation of intermediate mechanisms, such as G protein signaling and ion transport.
Genetic Disorders: Edwards Syndrome
Edwards syndrome, or Trisomy 18 (T18), is the second-most common trisomy, occurring in 1:3762 live births (Parker et al. 2010) . Because of high levels of prenatal mortality (75%) and low rates of postnatal survival (5% -10%) (Baty et al. 1994; Rasmussen et al. 2003) , T18 is poorly studied by comparison with DS. Mortality is most often linked to cardiac and renal malformations or to postnatal feeding difficulties resulting from central nervous system abnormalities. A 2011 study by Koide et al. (2011) sought to compare the genome wide transcriptome of five female fetuses with T18 to six female euploid fetuses. Two hundred and fifty-one (251) genes showed statistically significant differential expression, seven of which were located on chromosome 18, and six of which overlapped with the 419 genes differentially regulated in DS (Table 3 , Fig. 4 ). Specific genes of interest included ROCK1 (Rho-associated kinase 1), known to be involved in valvuloseptal and endocardial formation and ACTH (adrenocorticotropic hormone), which is required for normal morphological and functional development. Many of these genes were different from those first noted as differentially expressed by prior work in first trimester chorionic villi and cultured amniocytes (Altug-Teber et al. 2007) . Pathways analysis using IPA and DAVID implicated dysregulation of ion transport functioning, MHCII/T-Cell mediated immunity, adrenal development, and cardiovascular and respiratory system functions. These findings are reminiscent of many clinical observations in T18, including the adrenal cortical zone gross and microscopic hypoplasia.
Genetic Disorders: Neurological Transcripts in DS and T18
Although trisomies 18 and 21 are the most common live-born autosomal aneuploidies, little was known about the dysregulated biological Killer cell lectin-like receptor subfamily C, member 3 209176_at SEC23IP SEC23 interacting protein 211741_x_at PSG3
Pregnancy-specific beta-1-glycoprotein 3 223054_at DNAJB11 DnaJ (Hsp40) homolog, subfamily B, member 11 DS, Down syndrome (Slonim et al. 2009 ); Ob, obesity (Edlow et al. 2014 ); T18, Edwards syndrome (Koide et al. 2011 ); TTTS, Twin -twin transfusion syndrome (Hui et al. 2013b ); Turner, Turner syndrome (Massingham et al. 2014). pathways that resulted in well-characterized fetal morphological anomalies. In the studies of both DS and T18, differentially regulated genes included those that are thought to be expressed specifically from the central nervous system. This finding motivated a 2012 meta-analysis to mine previously published data (Slonim et al. 2009; Koide et al. 2011; Hui et al. 2012a ) with a specific focus on neural transcripts (Hui et al. 2012b ). Hui et al. identified the 536 genes universally present in the cffRNA of 12 of 12 euploid samples, 746 genes universally present in the cffRNA of five of five fetuses with T18, and the 1184 genes universally present in the cffRNA of seven of seven fetuses with DS. Using the functional analytics available through DAVID, IPA, and BioGPS, Hui et al. identified enrichment of the nervous system among differentially regulated genes in the aneuploid fetuses. This meta-analysis also reexamined genes previously identified as being differentially expressed in aneuploid fetuses and discovered that several are known to be expressed specifically from the central nervous system, including ones known to be critical for nervous system development. These genes included NEUROD2 (neuronal differentiation 2, downregulated in T18), which induces neurogenic differentiation and SOX11 (SRY-related HMGbox Gene 11, down-regulated in DS), a transcription factor that is essential for pan-neuronal protein expression and axonal growth of sensory neurons.
Genetic Disorders: Turner Syndrome
Turner syndrome (TS) is a sex chromosome aneuploidy (45, X female) characterized by anatomical differences, including short stature, a webbed neck, dysfunction of the kidneys, heart and ovaries, and an increased risk of autoimmune disorders. Comorbidities include obesity and glucose intolerance, scoliosis, atherosclerosis, hyperlipidemia, and juvenile rheumatoid arthritis. In a 2014 study, Massingham et al. (2014) compared five second trimester female fetuses, monosomic for the X chromosome, to five GAand sex-matched euploid control fetuses. Four hundred and seventy (470) differentially regulated genes were identified (BHp ,0.015). Genes showing the most extreme differential expression (fold-change 5) were submitted to IPA, and tissue-specific genes belonging to the top five most common organ systems were subjected to manual curation using Online Mendelian Inheritance in Man (OMIM). These in silico analyses revealed that among differentially regulated genes, there was enrichment for genes and pathways related to known symptoms of TS. This includes NFATC3, which is involved in perivascular tissue remodeling (of interest given that coarctation of the aorta is a feature of TS) and LDLR, which is involved in cholesterol homeostasis (of interest given that hyperlipidemia is a feature of TS). This enrichment also encompassed genes related to the hematologic/immune pathway, which may relate to the autoimmune disorders commonly seen in women with TS (Table 1) . Additionally, by identifying sets of differentially regulated genes, this study revealed several candidate genes not previously known to be associated with the condition, which are suitable for follow-up study. A "Turner syndrome transcriptome" was also created, comprised of genes for which each of the five TS samples consistently yielded a "present" signal on the microarray. The TS transcriptome was compared against other fetal transcriptomes (e.g., euploid [Hui et al. 2012a] , trisomies 18 and 21 [Hui et al. 2012b] ) and was subjected to BioGPS analysis to identify tissue-specific transcripts enriched specifically in amniotic fluid from fetuses with TS. The four studies presented above all examined the genome-wide changes to fetal gene expression that result from a single chromosome aneuploidy. As a whole, they suggest that the pathophysiology of these disorders does not arise from simple gene dosage effects of the aneuploid chromosome. Rather, an intragenomic web of expression misregulation contributes to create a distinct molecular and clinical phenotype that is characteristic of each disease, and shares few similarities with the others (Table 3 , Fig. 4) . Studies of nongenetic complications of pregnancy, such maternal obesity and further work on TTTS, have also yielded compelling evidence of disease-specific fetal molecular phenotypes, and are examined below.
Developmental Disorders: Twin-Twin Transfusion Syndrome TTTS is a complication of monochorionic diamniotic twin pregnancy associated with very high perinatal mortality rates (Shah and Chaffin 1989; Gonsoulin et al. 1990; Saunders et al. 1992) . Shared placental vascular anastomoses allow a net transfer of blood from one twin (the donor) to the other (the recipient). This disrupts regulation of fluid balance and fetal growth, leading to cardiovascular dysfunction and major neurodevelopmental irregularities in the fetus, as well as low birth-weight and premature delivery. TTTS diagnoses are further divided into stages; fetuses with stages II and III TTTS were the focus in this study. Stages II and III both show discordant AF volumes relative to a healthy fetus, but a stage III diagnosis involves a critically abnormal Doppler study for either the donor twin, the recipient twin, or both.
The typical treatment for TTTS is amnioreduction of the recipient twin combined with prenatal laser ablation of the shared placental anastomoses, which results in significantly improved survival of one or both fetuses (Senat et al. 2004; Roberts et al. 2008 ). Long-term health complications persist, however, including abnormal neurological function and increased risk of cardiac structural dysmorphology and long-term diastolic dysfunction. A long-standing question within the field has been whether these morbidities arise from the disease itself, or are complications resulting from the laser ablation treatment. As discussed above, preliminary examination of fetal gene expression in the context of TTTS suggested differential expression of the water-transport gene AQP1 in the recipient twin (Larrabee et al. 2005) . In 2013, Hui et al. revisited this disease, making a focused study of transcriptome-wide changes to fetal gene expression of the recipient twin in the second trimester, comparing gene expression between unaffected fetuses and fetuses with stage III TTTS, and comparing expression for fetuses with stages II and III TTTS.
In this study, eight recipient twins were each paired (for sex and GA) with eight healthy sin-gleton controls. Eight hundred and one (801) genes showed statistically significant differential gene expression between TTTS and unaffected fetuses. This list included genes with known functions in fluid homeostasis, blood pressure regulation and angiogenesis. Additionally, functional analyses of the 801 genes identified their enrichment in physiological systems consistent with known long-term complications of TTTS in the cardiovascular and nervous systems (Hui et al. 2013b) .
Real-time quantitative PCR validation was performed for six of these genes, selected for clinical significance and magnitude of gene expression fold-change. The microarray results were confirmed for four of the six, including NRXN3, NTRK3, FLT1, and AVPR1A, which are involved in synapse formation, nerve growth and formation of cardiac structures, angiogenesis and vasoconstriction, respectively. The amniotic fluid used in these studies was collected just before the initiation of laser ablation treatment. This allowed the investigators to conclude that the neurological and cardiovascular anomalies suggested by the differential gene expression analysis are intrinsic to TTTS itself, and are not a side effect of the laser ablation treatment.
In a second experiment from this same study, five stage II and five stage III samples were compared as groups in an unpaired analysis. Six hundred and eleven (611) genes showed statistically significant differential expression between these two groups. Functional analysis using IPA showed enrichment of genes associated with cardiovascular system development and function.
Environmental Exposures: Maternal Obesity
Maternal obesity is present in about one third of pregnancies in the United States (Flegal et al. 2012) . Maternal obesity during pregnancy has been associated with neurodevelopmental and metabolic conditions in the offspring, but the developmental underpinnings are poorly studied. In 2014, Edlow et al. conducted a study to examine whole-transcriptome differences in fetal gene expression from pregnancies of eight obese (BMI 30) and eight lean women (BMI , 25) . Two hundred and five (205) genes were found to be significantly differentially regulated between each of the eight pairs of fetuses, which were matched for sex and GA. At ninefold upregulation, apolipoprotein D (APOD) was the most up-regulated gene in fetuses of obese women. APOD is highly expressed in tissues of the central nervous system and is essential to proper lipid regulation. Functional analysis of the differentially regulated genes using IPA suggested down-regulation of apoptotic cell death, particularly in nervous system pathways involving the cerebral cortex. IPA analysis also allowed the prediction of activation of transcript regulators in fetuses of obese women, identifying three genes involved in estrogen and cytokine signaling, ESR1/2, FOS, and STAT3. Together, these findings suggest that maternal obesity creates a proestrogenic and proinflammatory intrauterine environment.
APPLICATIONS TO FETAL THERAPY
The initial goal of these studies was to assess fetal development in several organ systems at a discrete time point of fetal life in response to a known abnormality (genetic, hemodynamic, or environmental) . The detail and complexity revealed by these investigations has allowed for progression toward a second goal-the development of in utero treatments that can be offered at the time of disease diagnosis. Treatment at these critical early stages of development could mitigate the life-long health problems that originate in altered fetal development.
Work in our laboratory is already underway to develop prenatal treatments for oxidative stress in human fetuses with DS (Guedj and Bianchi 2013a; Guedj et al. 2014) . Compounds identified using the Connectivity Map database (see http://www.broadinstitute.org/cmap/), including the antioxidant drug apigenin, are being tested through in vitro studies on amniocytes from human AF and in vivo studies in the Ts1Cje mouse models of Down syndrome (Guedj et al. 2013b) . A preliminary stage of candidate drug testing is assessing the drug's toxicity and effects on cell proliferation in vitro through treatment of cells in culture. Secondarily, the efficacy of the drug in reducing oxidative stress is objectively measured by the COMET assay that quantifies the number of double stranded DNA breaks per cell (Tice et al. 2000) . In vivo studies include embryonic brain gene expression analysis, as well as neonatal and adult behavioral testing in apigenin-treated and untreated Ts1Cje mice and their littermate controls (Fig. 3) . The in vitro experiments require mitotically active cells, so fresh amniocytes are used in lieu of cffRNA.
Comparing AFS Cell-Free and Cellular RNA
The cffRNA found in AFS is a complex assortment of transcripts from many organs (Hui et al. 2012a) . With this in mind, we assessed the suitability of amniocytes as a proxy for cffRNA, by comparing gene expression in cffRNA and first passage amniocytes. In a previously unpublished study, whole amniotic fluid was collected from eight second-trimester fetuses (six singletons and one twin-pair, five male and three female) free from known structural and cytogenetic anomalies. The median GA was 17 wk (range 16 5 / 7 -22 4 / 7 wk). For each sample, the amniocytes were separated from the AFS by centrifugation and the cells were cultured for one passage. Thus, only mitotically active cells remained. Cellular RNA was then extracted from the amniocytes and cffRNA was extracted from the AFS of the same sample. Microarray expression analysis of this RNA resulted in surprising conclusions, including the fact that the cffRNA comprised a subset of the transcripts observed in the amniocytes (Fig. 5) . Analysis by BioGPS and DAVID of the genes that were significantly differentially expressed between the two data sets showed that relative to the AFS cffRNA, amniocytes were enriched for transcripts originating from endothelial, fibroblast, and aortic cells. Compared with amniocytes, cffRNA showed enrichment in transcripts originating from the tongue and intestine.
The higher quality of cellular RNA compared with cffRNA likely contributes to the finding that amniocytes contained transcripts for a greater number of genes (10,825 vs. 7531) (Fig. 5) . Cellular RNA is better protected from degradation, and so more consistently observed in the samples. Indeed, 52% of the genes observed in any one amniocyte RNA sample are observed consistently in all eight samples; this number drops to 36% for AFS cffRNA. Addi- tionally, it may be that although a diversity of fetal tissues contribute cells to AF, not all of these tissues or cells go on to contribute to the cffRNA found in AFS, resulting in a decreased number of transcripts in cffRNA relative to those seen in amniocyte cellular RNA.
Considering the presence of some of the genes of interest from the Hui et al. (2012a) "transcriptome" study shows that nearly all the genes that are observed in the AFS cffRNA are also observed in amniocyte RNA, including transcripts specific to the central nervous system (Table 4 ). There are some differences between the two AFS cffRNA studies, perhaps caused by the degraded nature of cffRNA resulting in inconsistent microarray signal calling, or to variations in the sex and GA of the studied fetuses. However, these data show that amniocytes are Genes for which probe set(s) known to have tissue-specific expression and are present in 12 of 12 amniotic fluid supernatant (AFS) cell-free fetal (cff ) RNA samples contributing to the amniotic fluid core transcriptome (Hui et al. 2012a) . Their presence in n of 8 AFS cffRNA or amniocyte (AC) RNA samples is indicated. reasonably equivalent to AFS, and can be used as a proxy for the fetus when testing the effects of different therapies.
FUTURE DIRECTIONS

RNA-Sequencing
With the increasing affordability and availability of RNA-Sequencing (RNA-Seq), many microarray-based laboratory and clinical applications are transitioning to this newer, more efficient platform. Pilot experiments from our laboratory comparing the suitability of RNASeq and expression microarrays for studying AFS cffRNA have shown that the former is currently more susceptible to the technical challenges of working with cffRNA (Zwemer et al. 2014) . cffRNA is by nature degraded and dilute, necessitating the development of a custom protocol for library creation. Work on this goal is currently underway in our laboratory, and will eventually allow our knowledge of fetal gene expression to expand to include many more genes than those represented on the HGU133 Plus 2.0 microarray.
The power of a whole-transcriptome approach lies in the ability to generate novel hypotheses for experimental approaches. In addition to creating new knowledge about relatively unknown aspects of fetal disease, these studies result in the identification of genes that are misregulated at the very time in development when essential neurological and physiological patterns are being established. Correcting gene misregulation through the use of pharmacological in utero treatments could minimize or prevent altered physiology. The work that began in DS in 2009 by examining cffRNA has resulted in preliminary experiments treating a mouse model of DS during pregnancy (Fig. 3) . The ultimate goal, however, is to translate the work to human pregnancies.
CONCLUDING REMARKS
Taken together, this set of disease studies has shown the unique power of cffRNA to identify novel aspects of the prenatal development of multiple fetal organs in both healthy and diseased states, allowing identification of candidate disease-related genes. These studies also support the hypothesis that the developmental underpinnings of a variety of genetic and environmental diseases can be observed as early as the second trimester of pregnancy. Furthermore, each of these studies supports the view that altered gene expression in these affected fetuses is a genome-wide phenomenon, extending beyond the causal aneuploidy, to produce a unique and characteristic pattern of fetal gene expression. Finally, several studies have shown that the source of cffRNA can be traced to a variety of fetal organs as well as the placenta, and that fetal transcriptomes between first-passage amniocytes and AFS cffRNA share many similarities, making both useful resources in the efforts to develop prenatal therapies.
